CORMEDIX INC. (CRMD) Debt Components
- 2025-12-31: Line of Credit Facility, Remaining Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD (m); Debt Instrument, Convertible, Threshold Consecutive Trading DaysDays 12 month · 30.00; Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemedpure 12 month · 100.00%.
- 2025-12-31: Line of Credit Facility, Remaining Borrowing CapacityUSD $15.00M; Debt Instrument, Face AmountUSD $1.00K; Debt Instrument, Convertible, Threshold Consecutive Trading DaysDays (m); Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemedpure (m).
- 2025-09-30: Line of Credit Facility, Remaining Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD (m); Debt Instrument, Convertible, Threshold Consecutive Trading DaysDays 9 month · 30.00; Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemedpure 9 month · 100.00%.
- 2025-09-30: Line of Credit Facility, Remaining Borrowing CapacityUSD $15.00M; Debt Instrument, Face AmountUSD $1.00K; Debt Instrument, Convertible, Threshold Consecutive Trading DaysDays (m); Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemedpure (m).
CORMEDIX INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Line of Credit Facility, Remaining Borrowing Capacity USD | Debt Instrument, Face Amount USD | Debt Instrument, Convertible, Threshold Consecutive Trading Days Days | Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed pure | Debt Instrument, Unamortized Discount USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger pure |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | (m) | (m) | 12 month · 30.00 | 12 month · 100.00% | (m) | (m) | (m) | (m) |
| 2025-12-31 | $15.00M | $1.00K | (m) | (m) | $5.37K | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | 9 month · 30.00 | 9 month · 100.00% | (m) | (m) | (m) | (m) |
| 2025-09-30 | $15.00M | $1.00K | (m) | (m) | $5.47M | (m) | (m) | (m) |
| 2025-08-12 | (m) | $150.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $15.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $100.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $100.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $100.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $100.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-08-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 10.00% |
| 2018-12-31 | (m) | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2012-11-13 | (m) | (m) | (m) | (m) | (m) | (m) | 9.00% | (m) |
| 2012-09-20 | (m) | (m) | (m) | (m) | (m) | (m) | 9.00% | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |